Ledger.Open graph →

SEC Form D · filed January 28, 2015

ZIOPHARM ONCOLOGY INC

Offering

$57.5M

Sold

$57.5M

Exemption

Rule 506(b)

Industry

Biotechnology

Location

Boston, MA

Type

—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (21)

Kevin G. Lafond · Boston, MAExec James A. Cannon · Boston, MADirector Randal J. Kirk · Boston, MADirector Murray Brennan · Boston, MADirector Michael Weiser · Boston, MADirector Caesar Belbel · Boston, MAExec Timothy Mcinerney · Boston, MADirector Jonathan Lewis · New York, NYExec · Director Bryan J. Weeks · Seattle, WADirector Michael D. Heffernan · Seattle, WADirector Bradford G. Jackson · Seattle, WAExec Wyche Fowler · Radnor, PADirector James D. Mitchell · Seattle, WAExec John J. Tobin · Seattle, WADirector Shenkman Capital Management Inc · New York, NYDirector Steven Heim · Boston, MAExec Matthew Zalosh · Boston, MADirector Nancy Spady · Boston, MADirector Wyche Fowler · Boston, MADirector Timothy Mcinerney · NEW YORK, NYDirector Jonathan Lewis · SAN DIEGO, CAExec · Director

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗